HomeInsightsStock Comparison

Marksans Pharma Ltd vs Natco Pharma Ltd Stock Comparison

Marksans Pharma Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: Aug 03, 2025

Key Highlights

  • The Latest Trading Price of Marksans Pharma Ltd is ₹ 224.6 as of 01 Aug 15:30.
  • The P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 26.5 on March 2025 . This represents a CAGR of 33.41% over 6 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 10076 crore on March 2025 . This represents a CAGR of 61.45% over 6 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Marksans Pharma Ltd for the Mar '25 is ₹ 724.98 crore as compare to the Dec '24 revenue of ₹ 709.7 crore. This represent the growth of 2.15% The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71%.
  • The ebitda of Marksans Pharma Ltd for the Mar '25 is ₹ 142.27 crore as compare to the Dec '24 ebitda of ₹ 166.61 crore. This represent the decline of -14.61% The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63%.
  • The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 90.73 crore over 8 quarters. This represents a CAGR of 13.49% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% .
  • The Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 19.26 % on March 2025 . This represents a CAGR of 10.12% over 6 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

About Natco Pharma Ltd

  • Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited.
  • It became a deemed public company with effect from 1 July 1992.
  • The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993.
  • The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.

Marksans Pharma Ltd News Hub

News

Marksans Pharma schedules board meeting

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 August ...

Read more

25 Jul 2025 10:49

News

Marksans Pharma AGM scheduled

Marksans Pharma announced that the 33th Annual General Meeting(AGM) of the company will be...

Read more

11 Jul 2025 17:41

News

Time-Cap Laboratories successfully concludes USFDA inspection

Marksans Pharma announced that its subsidiary, Time-Cap Laboratories Inc. has received the...

Read more

30 Jun 2025 12:56

News

Marksans Pharma rises after subsidiary gets EIR for New York-based facility from US FDA

In April this year, the United States Food and Drug Administration (US FDA) had conducted ...

Read more

30 Jun 2025 12:58

News

Marksans Pharma's UK arm gets marketing nod for Oxybutynin Oral solution from UKMHRA

Oxybutynin is used in the treatment of overactive bladder (OAB) symptoms. OAB is a collect...

Read more

19 Jun 2025 10:04

News

Relonchem receives marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution in UK

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

30 May 2025 09:13

Natco Pharma Ltd News Hub

News

Natco Pharma's API unit in Mekaguda clears USFDA inspection

Natco Pharma announced that the U.S.FDA has issued Establishment Inspection Report (EIR) f...

Read more

24 Jul 2025 15:34

News

Natco Pharma receives USFDA EIR for Hyderabad API facility

The US FDA had conducted an inspection at the company's aforementioned unit from 9 June to...

Read more

24 Jul 2025 15:09

News

Natco Pharma Ltd spurts 0.35%, gains for five straight sessions

Natco Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 1036....

Read more

18 Jul 2025 13:00

News

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility

In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 ...

Read more

20 Jun 2025 09:54

News

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

On conclusion of the inspection, the company received one observation in the Form-483. The...

Read more

14 Jun 2025 13:45

News

Natco Pharma's Mekaguda API unit completes USFDA inspection

NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active P...

Read more

13 Jun 2025 16:27

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Marksans Pharma Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Natco Pharma Ltd?

Market cap of Marksans Pharma Ltd is 10,178 Cr while Market cap of Natco Pharma Ltd is 16,591 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Natco Pharma Ltd?

The stock performance of Marksans Pharma Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Natco Pharma Ltd?

As of August 3, 2025, the Marksans Pharma Ltd stock price is INR ₹224.6. On the other hand, Natco Pharma Ltd stock price is INR ₹926.35.

How do dividend payouts of Marksans Pharma Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions